Pulse Biosciences, a company specializing in Nanosecond Pulsed Field Ablation (nsPFA) technology, announced that its Nanosecond PFA Percutaneous Electrode System will be featured in clinical science and video sessions at the North American Society for Interventional Thyroidology Annual Meeting. The system has FDA clearance for soft tissue ablation and is believed to be ideal for treating symptomatic benign thyroid nodules due to its nonthermal mechanism of action that limits scarring and spares critical anatomical structures.
The company’s Co-Chairman and CEO, Paul LaViolette, expressed gratitude to clinicians investigating the application of nsPFA technology in treating benign thyroid nodules and looks forward to future clinical studies. Scheduled programming at the conference includes a session on early clinical experiences with Nanosecond Pulsed Field Ablation and a video session showcasing key techniques with nanopulse by experts in the field.
Pulse Biosciences will also host an exhibit booth to highlight its technology at the conference. The company’s CellFX nsPFA technology delivers nanosecond pulses of electrical energy to clear cells nonthermally, with the potential to improve healthcare for patients and providers. Pulse Biosciences is actively developing the technology for use in the treatment of atrial fibrillation and other markets.
The company’s forward-looking statements emphasize the effectiveness of nsPFA technology and the potential for its Percutaneous Electrode System in ablation procedures, as well as the expectation of future clinical studies and regulatory submissions. Pulse Biosciences aims to continue innovating in the field of bioelectric medicine to enhance patient quality of life.
Source
Note: The image is for illustrative purposes only and is not the original image of the presented article.
